Gilead Sciences, Inc. (GILD) stock
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 11/30104% above fair value
$168.08+0.13 (+0.08%)
Close on Nov 13, 2026Market cap $208.48BP/E –Yield 1.88%
Gilead Sciences r&d expenses
Research and development expenses are spending on new products and technology.
Gilead Sciences's R&D Expenses for the twelve months ending Sep 30, 2026 was $6.33B, up 8.0% year over year. For fiscal 2025 it was $5.80B, down 1.8% from the year before. Over ten years it grew 6.8% a year on average. The highest annual figure on record is $5.91B in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.80B | -1.8% |
| FY2024 | Dec 31, 2024 | $5.91B | +3.3% |
| FY2023 | Dec 31, 2023 | $5.72B | +14.9% |
| FY2022 | Dec 31, 2022 | $4.98B | +8.2% |
| FY2021 | Dec 31, 2021 | $4.60B | -6.6% |
| FY2020 | Dec 31, 2020 | $4.93B | +21.5% |
| FY2019 | Dec 31, 2019 | $4.06B | +3.4% |
| FY2018 | Dec 31, 2018 | $3.92B | +5.0% |
| FY2017 | Dec 31, 2017 | $3.73B | -26.8% |
| FY2016 | Dec 31, 2016 | $5.10B | +69.1% |
| FY2015 | Dec 31, 2015 | $3.01B | +5.6% |
| FY2014 | Dec 31, 2014 | $2.85B | +34.6% |
| FY2013 | Dec 31, 2013 | $2.12B | +20.5% |
| FY2012 | Dec 31, 2012 | $1.76B | +43.2% |
| FY2011 | Dec 31, 2011 | $1.23B | +14.6% |
| FY2010 | Dec 31, 2010 | $1.07B | +14.2% |
| FY2009 | Dec 31, 2009 | $939.92M | +30.2% |
| FY2008 | Dec 31, 2008 | $721.77M | +22.1% |
| FY2007 | Dec 31, 2007 | $591.03M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.61B | +19.5% |
| Q2 FY2026 | Jun 30, 2026 | $1.76B | +18.3% |
| Q1 FY2026 | Mar 31, 2026 | $1.37B | -0.5% |
| Q4 FY2025 | Dec 31, 2025 | $1.58B | -3.5% |
| Q3 FY2025 | Sep 30, 2025 | $1.35B | -3.5% |
| Q2 FY2025 | Jun 30, 2025 | $1.49B | +10.4% |
| Q1 FY2025 | Mar 31, 2025 | $1.38B | -9.3% |
| Q4 FY2024 | Dec 31, 2024 | $1.64B | +16.5% |
| Q3 FY2024 | Sep 30, 2024 | $1.40B | -4.3% |
| Q2 FY2024 | Jun 30, 2024 | $1.35B | -4.0% |
| Q1 FY2024 | Mar 31, 2024 | $1.52B | +5.0% |
| Q4 FY2023 | Dec 31, 2023 | $1.41B | -9.0% |
| Q3 FY2023 | Sep 30, 2023 | $1.46B | +26.8% |
| Q2 FY2023 | Jun 30, 2023 | $1.41B | +27.7% |
| Q1 FY2023 | Mar 31, 2023 | $1.45B | +22.8% |
| Q4 FY2022 | Dec 31, 2022 | $1.55B | +14.0% |
| Q3 FY2022 | Sep 30, 2022 | $1.15B | +4.4% |
| Q2 FY2022 | Jun 30, 2022 | $1.10B | +0.9% |
| Q1 FY2022 | Mar 31, 2022 | $1.18B | +11.7% |
| Q4 FY2021 | Dec 31, 2021 | $1.36B | -7.4% |
| Q3 FY2021 | Sep 30, 2021 | $1.10B | -4.9% |
| Q2 FY2021 | Jun 30, 2021 | $1.09B | -15.9% |
| Q1 FY2021 | Mar 31, 2021 | $1.06B | +5.1% |
| Q4 FY2020 | Dec 31, 2020 | $1.47B | +33.4% |
| Q3 FY2020 | Sep 30, 2020 | $1.16B | +12.4% |
| Q2 FY2020 | Jun 30, 2020 | $1.30B | +30.6% |
| Q1 FY2020 | Mar 31, 2020 | $1.00B | -5.0% |
| Q4 FY2019 | Dec 31, 2019 | $1.10B | +29.0% |
| Q3 FY2019 | Sep 30, 2019 | $1.03B | +9.7% |
| Q2 FY2019 | Jun 30, 2019 | $995.00M | -16.5% |
| Q1 FY2019 | Mar 31, 2019 | $1.06B | +12.8% |
| Q4 FY2018 | Dec 31, 2018 | $852.00M | -25.9% |
| Q3 FY2018 | Sep 30, 2018 | $939.00M | +19.0% |
| Q2 FY2018 | Jun 30, 2018 | $1.19B | +38.0% |
| Q1 FY2018 | Mar 31, 2018 | $937.00M | +0.6% |
| Q4 FY2017 | Dec 31, 2017 | $1.15B | -4.8% |
| Q3 FY2017 | Sep 30, 2017 | $789.00M | – |
| Q2 FY2017 | Jun 30, 2017 | $864.00M | – |
| Q1 FY2017 | Mar 31, 2017 | $931.00M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.21B | – |
See a number that looks wrong?